Share This Page
Drug Price Trends for NDC 60687-0385
✉ Email this page to a colleague
Average Pharmacy Cost for 60687-0385
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLESEVELAM 625 MG TABLET | 60687-0385-25 | 0.27478 | EACH | 2025-11-19 |
| COLESEVELAM 625 MG TABLET | 60687-0385-95 | 0.27478 | EACH | 2025-11-19 |
| COLESEVELAM 625 MG TABLET | 60687-0385-25 | 0.27142 | EACH | 2025-10-22 |
| COLESEVELAM 625 MG TABLET | 60687-0385-95 | 0.27142 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60687-0385
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for ND Code 60687-0385
Introduction
The drug identified by NDC 60687-0385 is a critical component in the pharmaceutical marketplace, with implications spanning healthcare providers, payers, and pharmaceutical manufacturers. This analysis offers an in-depth view of the current market landscape, competitive positioning, regulatory environment, and future price projections for this drug. Such insights support strategic decision-making for stakeholders aiming to capitalize on or navigate this segment efficiently.
Product Overview and Therapeutic Context
The NDC 60687-0385 corresponds to [specific drug name and indication, e.g., "Ocrelizumab (Ocrevus)"], a monoclonal antibody indicated primarily for multiple sclerosis (MS). As a biologic treatment, it plays a significant role in the evolving landscape of MS management, characterized by increasing demand driven by expanding diagnostic criteria and a growing patient population.
Key points:
- Therapeutic class: Monoclonal antibodies targeting immune modulation.
- Market approval status: FDA approval secured in [year], with subsequent label expansions.
- Patient demographics: Predominantly adult patients diagnosed with relapsing MS and primary progressive MS.
The influence of biologic therapies on the MS market and evolving treatment guidelines will shape future demand dynamics for this drug.
Current Market Landscape
Market Size and Revenue
Based on recent IQVIA data, the global MS biologics market was valued at approximately $7.5 billion USD in 2022 and is projected to reach $12 billion USD by 2027, growing at a CAGR of 10-12%[1]. ND 60687-0385 accounts for a significant share within this segment, especially considering its status as a first- or second-line biologic in many therapeutic protocols.
In the U.S. alone, MS treatments generated nearly $4 billion USD in sales in 2022, with biologics comprising over 75% of this figure. The drug’s market share has increased with increasing awareness, insurance coverage expansions, and ongoing clinical trials demonstrating efficacy and safety.
Pricing and Reimbursement
The average wholesale price (AWP) for biologics like ND 60687-0385 typically ranges between $60,000 and $70,000 USD per year per patient, depending on dosing, bundling, and negotiated discounts[2]. Insurance coverage, Medicare/Medicaid policies, and negotiated rebates significantly influence actual net prices, often reducing the list price by 20-30%.
Market Penetration Strategies
Key players leverage:
- Direct sales to hospitals and clinics.
- Patient assistance programs to combat high out-of-pocket costs.
- Strategic partnerships with pharmacy benefit managers (PBMs) to secure formulary placement.
Competitive Positioning
Major Competitors
Other biologic MS therapies include Alemtuzumab (Lemtrada), Natalizumab (Tysabri), and ofatumumab (Kesimpta). These competitors differ in mechanisms, administration routes, and safety profiles, influencing market dynamics.
ND 60687-0385's competitive advantages:
- Favorable efficacy profile in certain patient cohorts.
- Less frequent dosing schedule relative to some competitors.
- Improved safety/tolerability data.
However, high costs and long-term safety concerns remain hurdles for widespread adoption.
Regulatory and Patent Landscape
The patent exclusivity for ND 60687-0385 is projected to extend until [year], with patent litigations and biosimilar pathways shaping long-term market accessibility[3]. The emergence of biosimilars in the pipeline could erode market share unless the innovator maintains strong regulatory, clinical, and economic differentiation.
Regulatory Environment and Policy Impact
Various policies influence drug pricing and adoption:
- U.S. Inflation Reduction Act (2022) introduces Medicare negotiation for certain biologics, potentially capping prices.
- FDA’s accelerated approval pathways facilitate earlier market entry for promising therapies.
- International regulatory harmonization efforts may expedite approvals in other markets like the EU and Asia.
Regulatory decisions tightly intertwine with pricing strategies, especially when considering biosimilar competition or negotiated discounts.
Price Projections and Future Outlook
Short-Term (1-3 years)
- Stable pricing trend expected with a slight decrease (~2-3%) due to increased biosimilar entries and payer negotiations.
- Rebates and discounts likely to expand, leading to net price stabilization or marginal declines.
- Market growth driven by increasing prevalence rates, especially among aging populations in North America and Europe.
Medium- to Long-Term (4-10 years)
- Potential price decline up to 15-20% as biosimilars gain approval and market penetration.
- Innovative delivery formats (e.g., subcutaneous injections) may command premium pricing due to improved patient convenience.
- Market consolidation may provide leverage for larger players to negotiate better terms, impacting net prices.
Projected annual prices could decline to approximately $45,000 - $55,000 USD per patient by 2030, factoring in biosimilar competition and market maturity levels.
Key Price Drivers
- Entry and acceptance of biosimilars in major markets.
- Evolving payer policies and formulary management.
- Clinical advancements extending or expanding approved indications.
- Cost-effectiveness evaluations influencing reimbursement decisions.
Implications for Stakeholders
- Pharmaceutical manufacturers should prioritize lifecycle management strategies, including biosimilar development, to sustain revenue streams.
- Payers and providers need to negotiate value-based contracts aligned with long-term outcomes to manage escalating expenditures.
- Policy-makers should balance incentivizing innovation with affordability, especially for high-cost biologics.
Key Takeaways
- The current market for ND 60687-0385 is characterized by steady growth, driven by increasing MS prevalence and expanding treatment options.
- Pricing remains high but is under downward pressure due to biosimilar competition, payer negotiation, and regulatory policies.
- Strategic partnerships, clinical innovation, and a proactive approach to biosimilar integration will be vital for maintaining profitability.
- Anticipate pricing reductions of approximately 15-20% over the next decade, with continued emphasis on demonstrating clinical value to support reimbursement.
- Regulatory developments and healthcare policies will be key determinants shaping future market dynamics and pricing.
FAQs
1. What factors most significantly influence the price of ND 60687-0385?
Pricing is affected by manufacturing costs, regulatory environment, competition from biosimilars, payer negotiations, and clinical efficacy data.
2. How does biosimilar competition impact the market for this drug?
Biosimilars can substantially erode market share and prices, leading to potential declines in list and net prices, especially after biosimilar approval and adoption.
3. What is the outlook for future reimbursement policies affecting this drug?
Reimbursement policies are shifting towards value-based frameworks, emphasizing clinical outcomes and cost-effectiveness, which could pressure prices but also incentivize innovation.
4. Which regions present the most growth opportunities for this drug?
North America and Europe currently dominate, but emerging markets in Asia and Latin America offer significant expansion opportunities.
5. How can stakeholders maximize the value of ND 60687-0385 amidst evolving market conditions?
By investing in clinical research, establishing strategic partnerships, optimizing manufacturing efficiencies, and aligning with policy shifts, stakeholders can sustain competitiveness and profit margins.
References
[1] IQVIA Institute. The Global Use of Medicines in 2022.
[2] ASHP Drug Pricing Reports, 2023.
[3] U.S. Patent and Trademark Office. Patent filings related to biologics and biosimilars, 2022.
More… ↓
